Clinical trial NCT05361915: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Official title: A Phase 2 Study of AbiVERtinib in Combination With Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (Maverick Trial)
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Prostate Cancer
Prostate Cancer Metastatic
Keywords: metastatic prostate cancer
castration-resistant prostate cancer
Lead sponsor: Sorrento Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2022-05-05
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.

Detailed description: This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer via assessment of 6-month radiographic progression-free survival. The study will include two cohorts, abiraterone-naive and abiraterone-progressing.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years of age
* Metastatic disease as identified by imaging
* Progressive mCRPC as defined by: 1) castrate levels of serum testosterone \< 50 ng/dL and 2) progressive disease
* Continued primary androgen deprivation with LHRH analogue (agonist or antagonist) if subject has not undergone bilateral orchiectomy
* Germline testing for HSD3B1. Confirmation of positivity for the adrenal-permissive HSD3B1(1245C) allele (germline heterozygous or homozygous) will be done centrally
* For abiraterone-progressing cohort, abiraterone must be the most immediate preceding line of therapy
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Adequate organ and marrow function

Exclusion Criteria:

* Significant small cell or neuroendocrine component or histology
* Prior enzalutamide, apalutamide, or darolutamide exposure for either hormone sensitive or CRPC. Prior abiraterone is prohibited for the abiraterone-naïve combination cohort
* Prior BTK inhibitor treatment
* Need for concurrent CYP3A inducers and inhibitors
* Any condition including the presence of laboratory abnormalities that places the patient at unacceptable risk if the patient was to participate in the study
* Corrected QT interval calculated by the Fridericia formula per electrocardiogram within 14 days before Cycle 1 Day 1
* Any uncontrolled active systemic infection including any infection requiring systemic IV treatment that was completed ≤ 7 days before Cycle 1 Day 1, including active infection with COVID-19, defined as 10 days from the end of COVID-19 symptoms
* Have human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or are at risk for HBV reactivation (at risk for HBV reactivation is defined as being HBs antigen positive, or anti-HBc-antibody positive), or are positive for HBV deoxyribonucleic acid (DNA). HCV ribonucleic acid (RNA) must be undetectable by laboratory test
* Imminent or established spinal cord compression based on clinical and/or imaging findings
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks prior to Cycle 1 Day 1
* Major surgery within 4 weeks before Cycle 1 Day 1. Minor surgeries within 10 days before Cycle 1 Day 1. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible
* Radiation therapy within 2 weeks before Cycle 1 Day
* Participation in another investigational trial and received treatment within 4 weeks before Cycle 1 Day 1
* Any other active malignancy at the time of first dose of study treatment or diagnosis of another malignancy within 2 years prior to Cycle 1 Day 1 that requires active treatment, except locally curable cancers
* Unable to swallow tablets/capsules whole

Primary outcomes:
measure: 6-month radiographic progression-free survival
timeFrame: baseline through study completion at up to approximately 63 months
Secondary outcomes:
measure: Overall Response Rate
timeFrame: baseline through study completion at up to approximately 63 months
measure: Duration of response
timeFrame: baseline through study completion at up to approximately 63 months
measure: Prostate-Specific Antigen (PSA) progression
timeFrame: baseline through study completion at up to approximately 63 months
measure: Safety and tolerability
timeFrame: baseline through study completion at up to approximately 63 months
measure: Time to occurrence of first skeletal event
timeFrame: baseline through study completion at up to approximately 63 months
measure: Time to first subsequent anti-cancer therapy
timeFrame: baseline through study completion at up to approximately 63 months
measure: 6-month radiographic progression-free survival (rPFS)
timeFrame: baseline through study completion at up to approximately 63 months
measure: Overall survival
timeFrame: baseline through study completion at up to approximately 63 months
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Moores Cancer Center
state: California
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: Sorrento Therapeutics, Inc.
name: Mike Royal, MD
role: STUDY_DIRECTOR
References: